Astellas Pharma Inc. (TYO: 4503)
Japan
· Delayed Price · Currency is JPY
1,750.50
-15.50 (-0.88%)
Oct 11, 2024, 3:15 PM JST
Astellas Pharma Revenue
Astellas Pharma had revenue of 473.12B JPY in the quarter ending June 30, 2024, with 26.17% growth. This brings the company's revenue in the last twelve months to 1.70T, up 12.57% year-over-year. In the fiscal year ending March 31, 2024, Astellas Pharma had annual revenue of 1.60T with 5.60% growth.
Revenue (ttm)
1,701.81B
Revenue Growth
+12.57%
P/S Ratio
1.84
Revenue / Employee
115.35M
Employees
14,754
Market Cap
3,138.87B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 1,603.67B | 85.05B | 5.60% |
Mar 31, 2023 | 1,518.62B | 222.46B | 17.16% |
Mar 31, 2022 | 1,296.16B | 46.64B | 3.73% |
Mar 31, 2021 | 1,249.53B | -51.32B | -3.94% |
Mar 31, 2020 | 1,300.84B | -5.51B | -0.42% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAstellas Pharma News
- 1 day ago - Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause - Benzinga
- 1 day ago - Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause - PRNewsWire
- 3 days ago - Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications - PRNewsWire
- 8 days ago - eyma Bahi appointed as head of Astellas Pharma Turkey, Middle East and Africa area - Zawya
- 10 days ago - Singlera Genomics and Astellas Present Methylation-based Organ Toxicity Detection at 2024 JSOT Annual Meeting - Business Wire
- 21 days ago - Astellas Receives Approval from the European Commission for VYLOY™ (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer - PRNewsWire
- 23 days ago - Astellas Announces FDA Listing of DIGITIVA™ for the Management of Heart Failure - PRNewsWire
- 4 weeks ago - Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024 - PRNewsWire